Provectus Pharmaceutical Reported Earnings

Provectus Pharmaceutical (PVCT) reported breakeven results on revenue of $0.00 million for the . . Revenue fell 100.00% compared to the same quarter a year ago.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.